Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.64 is 13% below its 5-year average of -1.46, around the middle of its 5-year range (-2.63–-0.26).
11.59% above its 12-month average of -1.85.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.45.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.64
EARNINGS PER SHARE (EPS) AVG TTM
-1.85
EARNINGS PER SHARE (EPS) AVG 3Y
-1.46
EARNINGS PER SHARE (EPS) AVG 5Y
-1.46
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.59%
CURRENT VS 3Y AVG
-12.14%
CURRENT VS 5Y AVG
-12.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Acumen Pharmaceuticals, Inc.
Market Cap
$150.59M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$151.52M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$153.31M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
Market Cap
$152.34M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
Market Cap
$147.54M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$154.07M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$154.72M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$155.61M
Earnings Per Share (EPS)
-28.87
TTM Avg
-17.24
3Y Avg
-11.28
5Y Avg
-9.01
Market Cap
$145.39M
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.66
3Y Avg
-1.77
5Y Avg
-1.60
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $150.59M | -1.64 | -1.85 | -1.46 | -1.46 |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.52M | -0.26 | -0.53 | -0.57 | -0.55 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.31M | -0.26 | -0.32 | -0.33 | -0.37 |
| Codexis, Inc. (CDXS)vs › | $152.34M | -0.34 | -0.70 | -0.76 | -0.63 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | -0.61 | -0.35 | -0.32 | -0.30 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.07M | -1.13 | -2.24 | -2.81 | -2.43 |
| LifeMD, Inc. (LFMDP)vs › | $154.72M | -0.51 | -0.38 | -0.76 | -1.59 |
| Minerva Neurosciences, Inc. (NERV)vs › | $155.61M | -28.87 | -17.24 | -11.28 | -9.01 |
| Immuneering Corporation (IMRX)vs › | $145.39M | -1.04 | -1.66 | -1.77 | -1.60 |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.68M | -12.04 | -8.05 | -55.02 | -123.25 |
Trailing EPS (TTM)
$-1.64
Forward EPS (Est.)
$-1.53
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.00 |
| 2024-12-31 | -1.71 |
| 2023-12-31 | -1.08 |
| 2022-12-31 | -1.06 |
| 2021-12-31 | -2.63 |
| 2020-12-31 | -0.26 |
| 2019-12-31 | -0.20 |
